News
Melior Pharmaceuticals Receives IND Clearance from US FDA for COVID-19 Therapeutic
- Melior’s therapeutic candidate, tolimidone, is:
-
- Expected to mitigate the probability and severity of COVID-19 subjects developing severe lung complications
-
- A repositioned drug that has been demonstrated to be safe and well-tolerated in previous clinical studies
Renowned Nutrition Expert Puts Rare Disease Day on the Radar
Dr. Virginia A. Stallings Discusses Individualized Nutrition Therapy for People with Cystic Fibrosis
Wellsheet Featured in KLAS Spotlight Targeting Physician Burnout
100% of Respondents Would Buy Wellsheet Again for Quick Access to Relevant Electronic Health Record Data to Reduce Time in the EHR
Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing
Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults
Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment
Annovis Bio’s Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study
ENB Therapeutics Demonstrated Early Efficacy in Phase I Clinical Trial of ENB-003 in Combination with Pembrolizumab
ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint
Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus
Findings support the potential of Immunome’s approach to developing IMM-BCP-01 as an optimized antibody cocktail for the treatment and prophylaxis of COVID-19